The primary aim of the present study was to assess the case for combined targeting of ER and PI3K pathway inhibition by examining an extended panel of ER-positive breast cancer cell lines using clinical grade PI3K and ER pathway inhibitors. This evidence concerns the gene ESR1 and breast carcinoma.